Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | Biomarkers | Research

Diagnostic accuracy of procalcitonin in adult non-neutropenic cancer patients with suspected infection: a systematic review and meta-analysis

Authors: Yi-Chih Lee, Hsin-Tzu Yeh, Sz-Wei Lu, Yi-Chun Tsai, Yu-Chen Tsai, Chieh-Ching Yen

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Procalcitonin (PCT) has garnered attention as a potential diagnostic biomarker for infection in cancer patients. We performed a systematic review and meta-analysis to evaluate the diagnostic accuracy of procalcitonin (PCT) and to compare it with C‐reactive protein (CRP) in adult non-neutropenic cancer patients with suspected infection.

Methods

A systematic literature search was performed in MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials to identify all relevant diagnostic accuracy studies. Original articles reporting the diagnostic accuracy of PCT for infection detection in adult patients with solid or hematological malignancies were included. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, area under the hierarchical summary receiver operator characteristic (HSROC) curve, and corresponding 95% confidence interval (CI) were calculated.

Results

Seven studies were included in the meta-analysis. The pooled sensitivity and specificity of PCT were 60% (95% CI [45–74%]) and 78% (95% CI [69–86%]). The diagnostic odds ratio was estimated at 5.47 (95% CI [2.86–10.46]). Three studies compared the diagnostic accuracies of PCT and CRP. The pooled sensitivity and specificity values for PCT were 57% (95% CI [26–83%]) and 75% (95% CI [68–82%]), and those for CRP were 67% (95% CI [35–88%]) and 73% (95% CI [69–77%]). The pooled sensitivity and specificity of PCT and CRP did not differ significantly (p = 0.61 and p = 0.63). The diagnostic accuracy of PCT was similar to that of CRP as measured by the area under the HSROC curve (0.73, CI = 0.61–0.91 vs. 0.74, CI = 0.61–0.95, p = 0.93).

Conclusion

While elevated PCT levels can be indicative of potential infection, they should not be solely relied upon to exclude infection. We recommend not using the PCT test in isolation; Instead, it should be carefully interpreted in the context of clinical findings.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ma Y, et al. Analysis of risk factors and clinical indicators in Bloodstream infections among patients with hematological malignancy. Cancer Manage Res. 2020;12:13579–88.CrossRef Ma Y, et al. Analysis of risk factors and clinical indicators in Bloodstream infections among patients with hematological malignancy. Cancer Manage Res. 2020;12:13579–88.CrossRef
2.
go back to reference Kartikasari AE, et al. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol. 2021;11:692142.CrossRefPubMedPubMedCentral Kartikasari AE, et al. Tumor-induced inflammatory cytokines and the emerging diagnostic devices for cancer detection and prognosis. Front Oncol. 2021;11:692142.CrossRefPubMedPubMedCentral
3.
go back to reference Roberts RR, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175–84.CrossRefPubMed Roberts RR, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. Clin Infect Dis. 2009;49(8):1175–84.CrossRefPubMed
4.
go back to reference Carling P, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24(9):699–706.CrossRefPubMed Carling P, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24(9):699–706.CrossRefPubMed
5.
go back to reference Toussaint E, et al. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer. 2006;14:763–9.CrossRefPubMed Toussaint E, et al. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer. 2006;14:763–9.CrossRefPubMed
6.
go back to reference Dornbusch HJ, et al. Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. Support Care Cancer. 2008;16(9):1035–40.CrossRefPubMed Dornbusch HJ, et al. Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. Support Care Cancer. 2008;16(9):1035–40.CrossRefPubMed
7.
go back to reference Haeusler GM, Carlesse F, Phillips RS. An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J. 2013;32(10):e390–6.CrossRefPubMed Haeusler GM, Carlesse F, Phillips RS. An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J. 2013;32(10):e390–6.CrossRefPubMed
8.
go back to reference Phillips RS, et al. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10(1):6.ADSCrossRefPubMedPubMedCentral Phillips RS, et al. Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med. 2012;10(1):6.ADSCrossRefPubMedPubMedCentral
9.
go back to reference Arif T, Phillips RS. Updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment and management of fever during neutropenia in children with cancer. Pediatr Blood Cancer. 2019;66(10):e27887.CrossRefPubMed Arif T, Phillips RS. Updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment and management of fever during neutropenia in children with cancer. Pediatr Blood Cancer. 2019;66(10):e27887.CrossRefPubMed
10.
go back to reference Wu C-W, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer. 2015;23(10):2863–72.CrossRefPubMed Wu C-W, et al. Does procalcitonin, C-reactive protein, or interleukin-6 test have a role in the diagnosis of severe infection in patients with febrile neutropenia? A systematic review and meta-analysis. Support Care Cancer. 2015;23(10):2863–72.CrossRefPubMed
11.
go back to reference Lin SG, et al. Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and Neutropenia–a systemic review and meta-analysis. Pediatr Infect Dis J. 2012;31(10):e182–8.CrossRefPubMed Lin SG, et al. Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and Neutropenia–a systemic review and meta-analysis. Pediatr Infect Dis J. 2012;31(10):e182–8.CrossRefPubMed
12.
go back to reference Matthew MCINNES. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388–96.CrossRef Matthew MCINNES. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388–96.CrossRef
13.
go back to reference Macaskill P et al. Cochrane handbook for systematic reviews of diagnostic test accuracy. 2010, Version. Macaskill P et al. Cochrane handbook for systematic reviews of diagnostic test accuracy. 2010, Version.
15.
go back to reference Whiting PF, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.CrossRefPubMed Whiting PF, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.CrossRefPubMed
16.
go back to reference Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865–84.CrossRefPubMed Rutter CM, Gatsonis CA. A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med. 2001;20(19):2865–84.CrossRefPubMed
17.
go back to reference Reitsma JB, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982–90.CrossRefPubMed Reitsma JB, et al. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982–90.CrossRefPubMed
18.
go back to reference Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12(14):1293–316.CrossRefPubMed Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12(14):1293–316.CrossRefPubMed
19.
go back to reference Kallio R, et al. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer. 2000;36(7):889–94.CrossRefPubMed Kallio R, et al. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer. 2000;36(7):889–94.CrossRefPubMed
20.
go back to reference Penel N, et al. [Fever and solid tumor: diagnostic value of procalcitonin and C-reactive protein]. Rev Med Interne. 2001;22(8):706–14.CrossRefPubMed Penel N, et al. [Fever and solid tumor: diagnostic value of procalcitonin and C-reactive protein]. Rev Med Interne. 2001;22(8):706–14.CrossRefPubMed
21.
go back to reference Zhao Z, et al. Role of C-reactive protein and procalcitonin in discriminating between infectious fever and tumor fever in non-neutropenic lung cancer patients. Med (Baltim). 2018;97(33):e11930.CrossRef Zhao Z, et al. Role of C-reactive protein and procalcitonin in discriminating between infectious fever and tumor fever in non-neutropenic lung cancer patients. Med (Baltim). 2018;97(33):e11930.CrossRef
22.
go back to reference Yang M, et al. Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies. PLoS ONE. 2019;14(12):e0225765.CrossRefPubMedPubMedCentral Yang M, et al. Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies. PLoS ONE. 2019;14(12):e0225765.CrossRefPubMedPubMedCentral
23.
go back to reference Blouin AG, et al. Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients. Clin Chim Acta. 2020;510:181–5.CrossRefPubMedPubMedCentral Blouin AG, et al. Utility of procalcitonin as a predictor of bloodstream infections and supportive modality requirements in critically ill cancer patients. Clin Chim Acta. 2020;510:181–5.CrossRefPubMedPubMedCentral
24.
go back to reference Ding S, et al. Diagnostic accuracy of Procalcitonin, Neutrophil-to-lymphocyte ratio, and C-Reactive protein in detection of bacterial infections and prediction of Outcome in Nonneutropenic Febrile patients with Lung Malignancy. J Oncol. 2020;2020:1–13. Ding S, et al. Diagnostic accuracy of Procalcitonin, Neutrophil-to-lymphocyte ratio, and C-Reactive protein in detection of bacterial infections and prediction of Outcome in Nonneutropenic Febrile patients with Lung Malignancy. J Oncol. 2020;2020:1–13.
25.
go back to reference Vassallo M, et al. Procalcitonin and C-Reactive Protein/Procalcitonin Ratio as Markers of Infection in patients with solid tumors. Front Med (Lausanne). 2021;8:627967.CrossRefPubMed Vassallo M, et al. Procalcitonin and C-Reactive Protein/Procalcitonin Ratio as Markers of Infection in patients with solid tumors. Front Med (Lausanne). 2021;8:627967.CrossRefPubMed
26.
go back to reference Page MJ, Higgins JP, Sterne JA. Assessing risk of bias due to missing results in a synthesis, in Cochrane Handbook for Systematic Reviews of Interventions; 2019. p. 349–374. Page MJ, Higgins JP, Sterne JA. Assessing risk of bias due to missing results in a synthesis, in Cochrane Handbook for Systematic Reviews of Interventions; 2019. p. 349–374.
27.
go back to reference Bischof JJ, et al. Emergency department disposition of non-neutropenic febrile patients with cancer. J Am Coll Emerg Physicians Open. 2021;2(5):e12576.CrossRefPubMedPubMedCentral Bischof JJ, et al. Emergency department disposition of non-neutropenic febrile patients with cancer. J Am Coll Emerg Physicians Open. 2021;2(5):e12576.CrossRefPubMedPubMedCentral
28.
go back to reference Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011;66(suppl2):ii33–ii40.PubMed Kibe S, Adams K, Barlow G. Diagnostic and prognostic biomarkers of sepsis in critical care. J Antimicrob Chemother. 2011;66(suppl2):ii33–ii40.PubMed
29.
go back to reference Huang YH, et al. Comparison of the Diagnostic accuracies of Monocyte distribution Width, Procalcitonin, and C-Reactive protein for Sepsis: a systematic review and Meta-analysis. Crit Care Med; 2023. Huang YH, et al. Comparison of the Diagnostic accuracies of Monocyte distribution Width, Procalcitonin, and C-Reactive protein for Sepsis: a systematic review and Meta-analysis. Crit Care Med; 2023.
30.
go back to reference Tan M, et al. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: a systematic review and meta‐analysis. J Cell Biochem. 2019;120(4):5852–9.CrossRefPubMed Tan M, et al. The diagnostic accuracy of procalcitonin and C-reactive protein for sepsis: a systematic review and meta‐analysis. J Cell Biochem. 2019;120(4):5852–9.CrossRefPubMed
32.
go back to reference Durnas B, et al. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets Therapy. 2016;9:469–75.PubMedPubMedCentral Durnas B, et al. Utility of blood procalcitonin concentration in the management of cancer patients with infections. OncoTargets Therapy. 2016;9:469–75.PubMedPubMedCentral
33.
go back to reference Stiletto R, Kirchner G, Ziering E. Procalcitonin (PCT) for monitoring ICU patients with severe polytrauma and early SIRS: results of a prospective study. Crit Care. 1998;2:1–60.CrossRef Stiletto R, Kirchner G, Ziering E. Procalcitonin (PCT) for monitoring ICU patients with severe polytrauma and early SIRS: results of a prospective study. Crit Care. 1998;2:1–60.CrossRef
Metadata
Title
Diagnostic accuracy of procalcitonin in adult non-neutropenic cancer patients with suspected infection: a systematic review and meta-analysis
Authors
Yi-Chih Lee
Hsin-Tzu Yeh
Sz-Wei Lu
Yi-Chun Tsai
Yu-Chen Tsai
Chieh-Ching Yen
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Biomarkers
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09174-7

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine